Patents by Inventor Shelley Force Aldred

Shelley Force Aldred has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11970540
    Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: April 30, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Shelley Force Aldred, Katherine Harris, Wim van Schooten
  • Publication number: 20240124599
    Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Application
    Filed: September 15, 2023
    Publication date: April 18, 2024
    Inventors: Nathan Trinklein, Shelley Force Aldred, Katherine Harris, Wim van Schooten
  • Publication number: 20240117046
    Abstract: Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.
    Type: Application
    Filed: December 7, 2023
    Publication date: April 11, 2024
    Inventors: Shelley Force Aldred, Wim van Schooten, Heather Anne N. Ogana, Laura Marie Davison, Katherine Harris, Udaya Rangaswamy, Nathan D. Trinklein
  • Publication number: 20240091264
    Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Application
    Filed: November 30, 2023
    Publication date: March 21, 2024
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, TeneoBio, Inc.
    Inventors: James N. Kochenderfer, Norris Lam, Nathan Trinklein, Katherine E. Harris, Shelley Force Aldred, Wim Van Schooten
  • Publication number: 20240018235
    Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: January 18, 2023
    Publication date: January 18, 2024
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • Patent number: 11873336
    Abstract: Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 16, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Shelley Force Aldred, Wim van Schooten, Heather Anne N. Ogana, Laura Marie Davison, Katherine Harris, Udaya Rangaswamy, Nathan D. Trinklein
  • Publication number: 20230272075
    Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: October 3, 2022
    Publication date: August 31, 2023
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • Publication number: 20230257473
    Abstract: Multi-specific, human heavy chain antibodies (e.g., UniAbs™) binding to BCMA are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of BCMA.
    Type: Application
    Filed: June 30, 2021
    Publication date: August 17, 2023
    Inventors: Nathan Trinklein, Katherine Harris, Harbani Malik, Ute Schellenberger, Omid Vafa, Shelley Force Aldred
  • Publication number: 20230203161
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 29, 2023
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim Van Schoofen, Shelley Force Aldred, Duy Pham, Starlynn Clarke
  • Patent number: 11613572
    Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: March 28, 2023
    Assignee: TeneoBio, Inc.
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • Publication number: 20230082151
    Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Application
    Filed: August 19, 2022
    Publication date: March 16, 2023
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • Publication number: 20230060847
    Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Application
    Filed: August 29, 2022
    Publication date: March 2, 2023
    Inventors: Nathan Trinklein, Shelley Force Aldred, Starlynn Clarke, Wim van Schooten
  • Publication number: 20230045100
    Abstract: Anti-BCMA heavy chain-only antibodies(HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Application
    Filed: June 29, 2022
    Publication date: February 9, 2023
    Inventors: Shelley Force Aldred, Nathan Trinklein, Katherine E. Harris, Kevin Dang, Wim van Schooten
  • Patent number: 11505606
    Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: November 22, 2022
    Assignee: TeneoBio, Inc.
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • Publication number: 20220332820
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Application
    Filed: November 23, 2021
    Publication date: October 20, 2022
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Duy Pham, Starlynn Clarke
  • Patent number: 11434299
    Abstract: Anti-BCMA heavy chain-only antibodies (HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 6, 2022
    Assignee: TeneoBio, Inc.
    Inventors: Shelley Force Aldred, Nathan Trinklein, Katherine E. Harris, Kevin Dang, Wim van Schooten
  • Patent number: 11427642
    Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: August 30, 2022
    Assignee: TENEOONE, INC.
    Inventors: Nathan Trinklein, Shelley Force Aldred, Starlynn Clarke, Wim van Schooten
  • Patent number: 11421027
    Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: August 23, 2022
    Assignee: TeneoOne, Inc.
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • Patent number: 11390681
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: July 19, 2022
    Assignee: TeneoTwo, Inc.
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Duy Pham, Udaya Rangaswamy
  • Publication number: 20220089729
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided. The invention further concerns methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by expression of one or more of the binding targets described herein.
    Type: Application
    Filed: June 14, 2021
    Publication date: March 24, 2022
    Inventors: Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Duy Pham, Udaya Rangaswamy